Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients

Amaral, Margarida D.

doi:10.1111/joim.12314

Cited by 95 publications

(87 citation statements)

References 109 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The novelty of these therapies is that, besides targeting the basic defect underlying CF, they are mutation specifi c. Although a monogenic disease, CF is infl uenced by a large number of different genes and biological pathways as well as by environmental factors that are diffi cult to assess. Therefore, every person with CF is unique and functional assessment of patients' tissues ex vivo is important for diagnosis and prediction of severity of this disease and assessment of responses to drugs for effective treatment (Amaral 2014 ). This is best achieved by a personalized approach to CF.…”

Section: Personalizing New Therapies For Cfmentioning

confidence: 99%

Textbook of Personalized Medicine

Jain¹

2015

View full text Add to dashboard Cite

Section: Personalizing New Therapies For Cfmentioning

confidence: 99%

Textbook of Personalized Medicine

Jain¹

2015

View full text Add to dashboard Cite

“…In addition, early diagnosis facilitates therapy of CF lung disease, although currently it can't be prevented [14]. On the other hand, the development of CFTR modulator therapy [81] offers the potential to ameliorate lung disease through enhanced chloride channel functioning.…”

Section: Newborn Screening: Principles and Practicesmentioning

confidence: 99%

Translational research advances a new era of prenatal diagnosis and newborn screening

Shulman

Farrell

2018

TRD

View full text Add to dashboard Cite

Abstract. This article provides a review of selected metabolic disorders resulting from genetic mutations and the methods used to identify them prenatally or facilitate diagnosis in the early neonatal period. Prenatal and neonatal diagnostic technologies have expanded and improved dramatically in the 21st century, as is their application in population-based screening and/or targeted assessment of at-risk couples. For instance, preimplantation genetic diagnosis has been a major advance. Emphasis herein has been placed on prototype diseases such as phenylketonuria, cystic fibrosis, and Tay-Sachs that have stimulated seminal efforts to improve medical practices in these fields. As more molecular strategies evolve, future developments in prenatal screening and diagnosis, along with newborn screening expansion, seem likely to continue rapid translation to the bedside.Keywords: Phenylketonuria, cystic fibrosis, Tay-Sachs disease, amniocentesis, chorionic villus sampling, tandem mass spectrometry Metabolic disorders resulting from genetic mutations have challenged obstetricians and pediatricians to develop diagnostic methods to identify them prenatally or in the early neonatal period [1]. The strategy of translational research has been ideal to close this gap as biotechnological advances are applied from the stage of novel laboratory developments to the practice of maternal-fetal medicine and neonatology. Although prenatal and neonatal diagnostic technologies have evolved gradually over four decades, they are expanding and changing dramatically in the 21st century, as is their application in population-based screening and/or targeted assessment of at-risk couples [1]. These changes have resulted in part from the Human Genome Project, a multicenter project supported by public and private funding geared to the sequencing of the human genome, which was completed in 2003. Clearly, the demand for prenatal genetic screening testing will continue as a result of individual and organizational advocacy efforts. In addition, advances in analytical technologies applying sophisticated cellular and molecular biology methods have increased the number and quality of tests available. Therefore, we are providing an overview with emphasis on prenatal diagnosis and suggest more comprehensive references in the bibliography [2][3][4][5]. We also recommend that the reader consult practice guidelines publications of

show abstract

“…9 Variations in the CFTR sequence can result in absence or dysfunction of the protein. This can occur in several different patterns that allow mutations to be characterized according to functional classes or according to therapeutics that may correct the defect.…”

Section: Figurementioning

confidence: 99%